🚀 VC round data is live in beta, check it out!
Immuneering Valuation Multiples
Discover revenue and EBITDA valuation multiples for Immuneering and similar public comparables like Probi, Surrozen, Cuorips, Nextbiomedical Co and more.
Immuneering Overview
About Immuneering
Immuneering Corp is a biopharmaceutical company. It is focused on improving patient outcomes across a spectrum of debilitating oncologic and neurologic diseases by applying deep knowledge of translational bioinformatics to every stage of the drug development process. The company's proprietary computational Disease Cancelling Technology platform enables Immuneering's drug discovery programs. The company also provides unparalleled computational biology capabilities to pharmaceutical and biotechnology companies.
Founded
2008
HQ
Employees
66
Website
Financials (LTM)
EV
$190M
Immuneering Financials
Immuneering reported last 12-month revenue of —.
In the same LTM period, Immuneering generated — in gross profit and had net loss of ($63M).
Revenue (LTM)
Immuneering P&L
In the most recent fiscal year, Immuneering reported revenue of — and EBITDA of ($59M).
Immuneering expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| EBITDA | — | XXX | ($59M) | XXX | XXX | XXX |
| Net Profit | ($63M) | XXX | ($56M) | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
Immuneering Stock Performance
Immuneering has current market cap of $359M, and enterprise value of $190M.
Market Cap Evolution
Immuneering's stock price is $5.55.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $190M | $359M | -0.4% | XXX | XXX | XXX | $-0.87 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialImmuneering Valuation Multiples
Immuneering trades at (3.2x) EV/EBITDA.
EV / Revenue (LTM)
Immuneering Financial Valuation Multiples
As of April 18, 2026, Immuneering has market cap of $359M and EV of $190M.
Equity research analysts estimate Immuneering's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Immuneering has a P/E ratio of (5.7x).
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $359M | XXX | $359M | XXX | XXX | XXX |
| EV (current) | $190M | XXX | $190M | XXX | XXX | XXX |
| EV/EBITDA | — | XXX | (3.2x) | XXX | XXX | XXX |
| EV/EBIT | (2.8x) | XXX | (3.2x) | XXX | XXX | XXX |
| P/E | (5.7x) | XXX | (6.4x) | XXX | XXX | XXX |
| EV/FCF | — | XXX | (4.2x) | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Immuneering Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
Immuneering Margins & Growth Rates
Immuneering's revenue in the last fiscal year grew by —.
Immuneering's revenue per employee in the last FY averaged $0.0M, while opex per employee averaged $0.9M for the same period.
Immuneering Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| EBITDA Growth | — | XXX | (7%) | XXX | XXX | XXX |
| Revenue per Employee | — | XXX | $0.0M | XXX | XXX | XXX |
| Opex per Employee | — | XXX | $0.9M | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Immuneering Public Comps
See public comps and valuation multiples for other Biopharmaceuticals comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| Immuneering | XXX | XXX | XXX | XXX | XXX | XXX |
| Probi | XXX | XXX | XXX | XXX | XXX | XXX |
| Surrozen | XXX | XXX | XXX | XXX | XXX | XXX |
| Cuorips | XXX | XXX | XXX | XXX | XXX | XXX |
| Nextbiomedical Co | XXX | XXX | XXX | XXX | XXX | XXX |
| CHO Pharma | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Immuneering M&A Activity
Immuneering acquired XXX companies to date.
Last acquisition by Immuneering was on XXXXXXXX, XXXXX. Immuneering acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by Immuneering
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialImmuneering Investment Activity
Immuneering invested in XXX companies to date.
Immuneering made its latest investment on XXXXXXXX, XXXXX. Immuneering invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by Immuneering
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Immuneering
| When was Immuneering founded? | Immuneering was founded in 2008. |
| Where is Immuneering headquartered? | Immuneering is headquartered in United States. |
| How many employees does Immuneering have? | As of today, Immuneering has over 66 employees. |
| Who is the CEO of Immuneering? | Immuneering's CEO is Benjamin J. Zeskind. |
| Is Immuneering publicly listed? | Yes, Immuneering is a public company listed on Nasdaq. |
| What is the stock symbol of Immuneering? | Immuneering trades under IMRX ticker. |
| When did Immuneering go public? | Immuneering went public in 2021. |
| Who are competitors of Immuneering? | Immuneering main competitors are Probi, Surrozen, Cuorips, Nextbiomedical Co. |
| What is the current market cap of Immuneering? | Immuneering's current market cap is $359M. |
| Is Immuneering profitable? | No, Immuneering is not profitable. |
| What is the current net income of Immuneering? | Immuneering's last 12 months net income is ($63M). |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.